TY - JOUR T1 - Clinical Outcomes and Safety of Topical Treatments for Palmoplantar Psoriasis: A Comparative Study AU - Parvathi, P.A. AU - Pravin, A.J.S. AU - Jaffer, Azeem AU - Simon, J. JO - Research Journal of Medical Sciences VL - 18 IS - 10 SP - 621 EP - 624 PY - 2024 DA - 2001/08/19 SN - 1815-9346 DO - makrjms.2024.10.621.624 UR - https://makhillpublications.co/view-article.php?doi=makrjms.2024.10.621.624 KW - Palmoplantar psoriasis KW - calcipotriol KW - betamethasone KW - topical therapy KW - PASI KW - patient satisfaction AB -

Palmoplantar psoriasis (PPP) is a chronic, treatment‐resistant inflammatory skin condition primarily affecting the palms and soles. Despite the availability of multiple topical therapies, a lack of comparative studies limits evidence‐based treatment recommendations. To evaluate and compare the efficacy, safety and patient satisfaction of three topical treatment modalities for PPP: corticosteroid‐salicylic acid combination, calcipotriol‐betamethasone combination and coal tar‐urea combination. A prospective, comparative study was conducted over six months with 45 patients aged 18‐65 years diagnosed with PPP. Patients were divided into three equal groups (n=15 each) and treated with one of the following regimens: Group A received clobetasol propionate 0.05% with salicylic acid 6%., Group B received calcipotriol 0.005% with betamethasone dipropionate 0.05% and Group C received coal tar 3% with urea 10%. Treatments were applied twice daily for 12 weeks. Efficacy was assessed using Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI) and patient satisfaction. Safety was evaluated by documenting adverse effects. All groups showed significant PASI reductions, with the greatest improvement observed in Group B (p<0.05). Group B also demonstrated the highest patient satisfaction (VAS 8.9±1.0) and fewest adverse effects. Group A achieved moderate efficacy, while Group C was less effective but well‐tolerated. The calcipotriolbetamethasone combination was the most effective and well‐tolerated treatment for PPP, providing significant clinical improvement and high patient satisfaction. These findings support its use as a preferred first‐line therapy for PPP. Further studies with larger sample sizes are recommended.

ER -